ESPR Stock Analysis: Buy, Sell, or Hold?

ESPR - Esperion Therapeutics, Inc.

PHARMACEUTICAL PREPARATIONS
$2.61
0.00 (0.00%) ▲
5d: -8.42%
30d: -10.31%
90d: -29.46%
HOLD
LOW Confidence
Protect Your ESPR Gains
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 05, 2026 30d
Smart Money Accumulation

ESPR is down 4.6% this week, but smart money is accumulating calls. Top strike: $3.5 2026-06-18 with 7,480 OI. Call ratio: 100% View Scanner →

Strength: 7.3/10

Get Alerted When ESPR Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
📊 HOLD: ESPR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$14.28
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.87
70.6% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: ESPR is currently trading at $2.61, which is considered slightly low relative to its 30-day fair value range of $2.53 to $3.11. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.9) compared to its historical average (62.1). Remarkably, the market is currently pricing in an annual earnings decline of 47.7% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, ESPR is in a strong uptrend. Immediate support is located at $2.47, while resistance sits at $2.91.

Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.99 (+167.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position SLIGHTLY LOW
Fair Price Range $2.53 - $3.11
Company Quality Score 50/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 79.5%

Protect Your Profits

Holding ESPR? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

  • BULLISH: Price oversold vs 30-day range
  • NEUTRAL: Mixed technical signals (45/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 167.9% below Wall St target ($6.99)
  • CAUTION: Recommendation downgraded due to -8.4% 5-day decline

Fair Price Analysis

30-Day Fair Range $2.53 - $3.11
Current vs Fair Value SLIGHTLY LOW

Support & Resistance Levels

Support Level $2.47
Resistance Level $2.91
Current Trend Strong Uptrend
Technical data as of Apr 2, 2026

Fundamental Context

Forward P/E (Next Year Est.) 8.90
Wall Street Target $6.99 (+167.9%)
Revenue Growth (YoY) 143.7%
Profit Margin -5.6%
Valuation Discount vs History -47.7% cheaper
PE vs Historical 8.9 vs 62.1 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -47.7% (market-implied from PE analysis)
1-Year Target $2.35 (-10%)
2-Year Target $2.11 (-19%)
3-Year Target $1.90 (-27%)
3-Yr Target (if PE normalizes) (PE: 9→62) $13.28 (+409%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 20.6, Growth: 2105.3%) $20.36 (+680%)
Base: (SPY PE: 8.9, Growth: 2105.3%) $8.81 (+238%)
Bear: (PE: 7.6, Growth: 2105.3%) $7.49 (+187%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.9 to 62.1
Stabilization Target: $18.21 (+597.9%)
PE Expansion Potential: +597.9%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: April 04, 2026 2:59 AM ET
Data refreshes hourly during market hours. Next update: 3:59 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Halladay SELL 6424 shares 2026-03-17
Benjamin Looker SELL 5708 shares 2026-03-17
Benjamin Looker SELL 1689 shares 2026-01-20

Unlock Insider Activity

See real-time buying/selling by company executives for ESPR.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences I…
STRONG BUY
25 analysts
$178 63 BUY
ZTS
Zoetis Inc
STRONG BUY
19 analysts
$151 63 BUY
LNTH
Lantheus Holdings Inc
STRONG BUY
13 analysts
$91 61 BUY
BCRX
BioCryst Pharmaceuticals…
STRONG BUY
12 analysts
$21 55 HOLD
HCM
HUTCHMED DRC
STRONG BUY
14 analysts
$21 56 HOLD

Advanced ESPR Option Strategies

Professional options setups generated by AI based on today's ESPR price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ESPR

ESPR Technical Chart ESPR Price Prediction ESPR Earnings Date ESPR Investment Advisor ESPR Fair Price Analyzer ESPR Options Advisor ESPR Options Chain ESPR Options Analysis ESPR Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals